Form 4 for BDX Becton Dickinson
Accepted 2026-06-03 12:44:24 ET · period of report 2026-06-01 · accession 0001628280-26-040095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $126.16 | +20.2K | 125.7K | +19% | +$2.55M |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | D - Sale to Iss | $146.15 | -17.4K | 108.2K | -14% | -$2.55M |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | S - Sale+OE | $146.35 | -2,764 | 110.2K | -2% | -$404.5K |
| DT | 2026-06-03 12:44 | 2026-06-01 | BDX | Polen Thomas E Jr | COB, CEO, Pres, Dir | M - OptEx | $0.00 | -20.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | M | A | 20,209 | $126.16 | 125,680 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-01 | D | D | 17,445 | $146.15 | 108,235 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-01 | S | D | 2,764 | $146.35 | 110,163 | D | — | — | (F1) The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. (F2) Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. |
| 4 | Derivative | Stock Appreciation Rights | 2026-06-01 | M | D | 20,209 | $0.00 | 0 | D | $126.16 · 2017-11-26 to 2026-11-26 | 20,209 Common Stock | (F3) Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. (F3) Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. (F4) The stock appreciation rights vested in four annual installments beginning November 26, 2017. |